ABSTRACT
Objective: To test the coalescence effect of two chemotherapy drugs at low effective dose (cisplatin and taxotere) combined with pomegranate juice on A549 cancer cells. Methods: Infrared spectroscopy method is a qualitative test that was performed to ensure the existence of the phytochemicals providing the antioxidant activity through the presence of the hydroxyl group (-OH). The viability of A549 cell line and normal MCs was tested using the neutral red uptake, Clonogenic survival, XTT and Cell migration assays. Results: Our results showed that this combination firstly led to a greater decrease in the viability of cells comparing to those treated with chemotherapy drugs alone, and secondly led to a significant reduction in cell migration. Conclusions: These data suggest a synergistic effect between the pomegranate and cisplatin which makes probably this combination a powerful option for treating lung adenocarcinoma and in parallel minimizing the systemic side effects.
ABSTRACT
Objective:To test the coalescence effect of two chemotherapy drugs at low effective dose (cisplatin and taxotere) combined with pomegranate juice on A549 cancer cells.Metoods:Infrared spectroscopy method is a qualitative test that was performed to ensure the existence of the phytochemicals providing the antioxidant activity through the presence of the hydroxyl group (-OH).The viability of A549 cell line and normal MCs was tested using the neutral red uptake,Clonogenie survival,XTT and Cell migration assays.Results:Our results showed that this combination firstly led to a greater decrease in the viability of cells comparing to those treated with chemotherapy drugs alone,and secondly led to a significant reduction in cell migration.Conclusions:These data suggest a synergistic effect between the pomegranate and cisplatin which makes probably this combination a powerful option for treating lung adenocarcinoma and in parallel minimizing the systemic side effects.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and toxic reaction of bronchial artery infusion(BAI)chemotherapy com-bined with Cinobufacini capsule in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:A total of 126 cas-es of advanced NSCLC diagnosed in stage Ⅲb-Ⅳ were randomly divided into observation and control group,63 cases in each group. Both of them were treated by BAI with taxotere/cisplatin(TP regimen),once every three weeks for a cycle,a total of 5 cy-cles;observation group was additionally given Cinobufacini capsule 500 mg/time,three times a day,on the basis of BAI chemo-therapy,for 15 weeks. Clinical efficacy,KPS,survival rate and toxic reaction of 2 groups were observed. RESULTS:The total ef-fective rate(82.54%)of observation group was better than that(63.49%)of control group,with statistical significance(P<0.05). KPS score of observation group was significantly better than that of control group,with statistical significance (P<0.05). 1-year survival rate of observation group and control group were 65.08% and 30.15%,2-year survival rate of them were 19.05% and 4.76%,with statistical significance(P<0.05). Adverse reactions of two groups was mainly marrow suppression and gastrointesti-nal reaction,marrow suppression degree and the incidence of nausea and vomiting in observation group was lighter than control group,with statistical significance (P<0.05). CONCLUSIONS:BAI combined with Cinobufacini capsule in the treatment of ad-vanced NSCLC can improve short-term curative effect and long-term survival rate,and can improve the survival quality with little toxic effect.
ABSTRACT
OBJECTIVE:To observe the short-term efficacy and toxicity reaction of 2 regimens of taxotere combined with epi-rubicin in the neoadjuvant chemotherapy of breast cancer. METHODS:78 patients with locally advanced breast cancer were random-ly divided into TEC group(45 cases)and TE group(33 cases). TEC group was treated with taxotere 75 mg/m2 by intravenous in-jection,d1+epirubicin 60 mg/m2 by intravenous injection,d1+cyclophosphamide 500 mg/m2 by intravenous injection d1. TE group was treated with taxotere 75 mg/m2 by intravenous injection,d1+epirubicin 60 mg/m2 by intravenous injection,d1. 21 days were a treatment course for 2 groups,and there were totally 4-6 courses. In the 2 groups,efficacy and toxicity reaction were evaluated af-ter 4 weeks at least,and survival rate of 6 months was followed-up. RESULTS:The differences were not statistically significant in the short-term efficacy and toxicity reaction and survival rate between 2 groups (P>0.05). CONCLUSIONS:TEC and TC have similar short-term efficacy and safety in the treatment of locally advanced breast cancer. Both of them can be used as adjuvant medi-cines for neoadjuvant chemotherapy.
ABSTRACT
Objective To confirm whether taxotere combined with mild hyperthermia will have synergistic effects,and to explore their joint mechanism of action.Methods Firstly the effective concentration of taxotere was determined by using MTT method to observe the effect of docetaxel on proliferation of human breast cancer cell line MCF-7.Then three samples of in vitro cultured human breast carcinoma MCF-7 cells were prepared,termed the the taxotere group,the taxotere plus mild hyperthermia group and the control group,and treated with effective concentration of taxotere exclusively or in combination with mild hyperthermia,or left without any special treatment.The taxotere plus mild hyperthermia group was subdivided into 5 subgroups according to the temperatures used (39.0 ℃,39.5 ℃,40.0 ℃,40.5 ℃,41.0 ℃) MTT assays were used to measure the proliferation and invasive capacity of the cells and their effective concentrations.Flow cytometry was used to detect cell apoptosis rates and any cell cycle changes in the control group.Western blotting was used to detect any changes in the expression of mitogen-activated protein kinases (MAPKs),Bcl-2/Bax,heat shock protein-70 (HSP-70) and P-gp.Results The taxotere with mild hyperthermia group demonstrated a significantly higher rate of apoptosis than that in the taxotere and control groups.There were also more cells in the G2/M phase observed.Combining taxotere with mild hyperthermia was found after 24 h to have significantly increased p-ERK,p-JNK,p38,HSP-70 and P-gp protein levels and to have significantly decreased Bcl-2 protein expression in contrast with the other two groups.Conclusions Combining taxotere with mild hyperthermia showed synergistic effects in vitro.It seemed to be limiting the accumulation of MCF-7 cells in the G2/M phase and activating the signal pathways of MAPKs while inhibiting the activation of Bcl-2/Bax signal pathways.Combining taxotere and mild hyperthermia can accelerate the expression of HSP70 and P-gp in MCF-7 cells.Hyperthermia might induce chemotherapy resistance.
ABSTRACT
Objective To evaluate the efficacy and toxicity of three dimensional confoimal radiotherapy(3D-CRT)concurrent taxotere for patients with esophageal carcinoma.Methods Ninty-six patients with esophageal carcinoma were received 3D-CRT concurrent taxotere,the radiotherapy was carried out by 3D-CRT,to a total dose 95% PTV 66Gy/33f/6.6W.The trial results were evaluated by the clinical curative effect criterion.Results Complete response rate(CR)was 67.7%.Overall response rate(CR+PR)was 89.6%.The local control rates of 1 year and 3 years were 86.5% and 63% ,respectively.The survival rates of 1 year and 3 years were 76.1% and 50.0%,respectively.The main acute toxic effect was radioactive esophagitis.Conclusions 3D-CRT concurrent taxotere could improve the overall response rate and survival rate of esophageal carcinoma.Although it increased the acute toxic effect,the patients could accept the therapy.
ABSTRACT
Objective To study the effects of survivin antisense RNA on SGC7901 cell’s apoptosis and chemosensitivity to taxotere, and to investigate its effect on the expression of multi-drug resistance gene-1 (MDR-1). Methods Survivin antisense eukaryotic vector anti-pcDNA3-svv was transfected into SGC7901 cell lines by lipofectamine and positive clones were screened out then. Survivin protein and MDR-1 mRNA were measured by western blot and RT-PCR, respectively. Apoptosis that was induced by anti-pcDNA3-svv was observed by electronic microscope, and the sensitivity of SGC7901 cell to taxotere was examined by MTT. Results The expressions of survivin protein and MDR-1 mRNA in transfected SGC7901 cells both decreased more significantly than that of non-transfected cells (P
ABSTRACT
OBJECTIVE:To investigate the efficacies and safety of paclitaxel (PTX) versus Taxotere (TXT) and fluorouracil (5-FU) versus cisplatin (DDP) (PCF vs.DCF regimens) in the treatment of advanced gastric cancer (AGC).METHODS:60 cases of AGC were divided into two groups according to different regimens.The patients in group PCF (n=30) received 35～50 mg?m-2 PTX via ivgtt for 3 hours on the 1st,8th,15th day.The patients in group DCF (n=30) received 35 mg?m-2 TXT via ivgtt for 1 hour,on the 1 st,8th,15th day.Both groups were given 750 mg?m-2 5-FU with continuous infusion administration from the 1st to 5th day and 20 mg?m-2 DDP via ivgtt for 2 hours from the 1st to 5th day with treatment course of 28 d.Recent efficacy and safety were evaluated after two cycle of treatment and long-term efficacy were followed up continuously.RESULTS:Overall response rate (ORR) was 50.0% for group PCF and 46.6% for group DCF.Disease control rate (DCR) was 66.6% in group PCF and 63.3% in group DCF.The median survival time (MST) was 10.4 months in group PCF and 9.6 months in group DCF.One-year survival rates were 35.7% for group PCF and 34.4% for group DCF.There was no statistically significance in recent and long-term efficacy between two groups.Grade Ⅲ/Ⅳ toxicities represented as bone marrow depression,nausea,vomiting and alopecia in two groups.Grade Ⅳ neutropenia and the overall incidence of anemia,DCF was significantly higher than the PCF group.CONCLUSION:PCF and DCF regimens have similar response in the treatment of advanced gastric cancer.Drug toxicity of two regimes are different while both of them are tolerable well.
ABSTRACT
Purpose:To compare the response and toxic reaction of 3-weeks’ and weekly taxotere/cisplation treatment in non-small-cell lung cancer. Methods:Group A: Taxotere 75mg/m~2 IV d 1,cisplatin 25mg/m~2 d 1-3 q3-4w; Group B: Taxotere 60 mg IV d1, taxotere 40 mg IV d8,d15, cisplatin 25 mg/m~2 IV d 1,d 8,d 15 q3-4w. The clinical responses were assessed after two cycles. Toxicity was assessed every cycle. Results:There was no CR in the 71 cases . There were 14 PR, 13 SD in group A; there were 16 PR, 14 SD in group B. The overall response rates were 41.2% and 44.4% in group A and B. The rates of grade Ⅲ/Ⅳ neatropenia were 70.6% and 25% in group A and B. The major nonhematologic toxicity was weakness. The rates of weakness were 44.1% and 19.4% in group A and B. Conclusions:The response rates were similar between groups A and B. The occurrence of hematologic toxicity and weakness were lower in weekly treatment.
ABSTRACT
Objective To investigate the efficacy and safety of zoledronic acid combined with taxotere in treatment of breast cancer patients with multiple bone metastases and negative hormone receptors.Methods Thirty-six breast cancer patients with multiple bone metastases were randomized devided into two groups: Group A(zoledronic acid plus taxotere) and Group B(zoledronic acid alone).The effect in the two groups was compared.Results Relief of bone pain,improvement in quality of life,and toxic side effects between the two groups showed no significant difference.The effect on bone metastases was 66.7%(12/18)in group A,which was significantly higher than that in group B(11.1%,2/18)(P
ABSTRACT
OBJECTIVE:To observe the short-term curative effects of 3-dimensional conformal radiotherapy(3DCRT) combined with taxotere on locally advanced non-small cell lung cancer.METHODS:83 patients Ⅲ a or Ⅲ b with locally advanced non-small cell lung cancer were divided randomly into the treatment and control group.The treatment group were treated with 3DCRT in combination with taxotere,while the control group were treated with single 3DCRT.RESULTS:The effective rates in the treatment and control group were 88.37% and 62.50%(P